(Q36589866)

15 August 2017

1 reference

title

Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells (English)

1 reference

15 August 2017

1 reference

1 reference

3

Eric J Small

1 reference

15 August 2017

Amy M Lin

1

1 reference

15 August 2017

Robert M Hershberg

series ordinal

2

1 reference

15 August 2017

publication date

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

24

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

434-441

1 reference

15 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Current developments in cancer vaccines and cellular immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Dendritic cells as adjuvants for immune-mediated resistance to tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Clinical use of tumor markers in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

CD4 T cells and their role in antitumor immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

The role of CD4+ T cell responses in antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.010

10.1016/J.UROLONC.2005.08.010

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference